Rezolve AI PLC issued a statement on April 14, 2026 that sharply criticized Commerce.com’s board for adopting a poison pill. The statement, released the same day the board adopted the rights plan, marks the first time Rezolve has publicly challenged a rival board’s defensive strategy. The move signals Rezolve’s active opposition to the board’s tactic and could influence shareholder sentiment and future merger discussions.
The poison pill, formally known as a rights plan, was triggered when Commerce.com’s board adopted a plan that would allow the company to issue new shares at a discount to deter a hostile takeover. The plan’s mechanics set a 10% ownership threshold for general acquirers and a 20% threshold for passive institutional investors, with an exercise price of $13.00 per one‑thousandth of a share of Series A Junior Participating Preferred Stock. Commerce.com’s board justified the plan by arguing that Rezolve’s offer “significantly undervalues the Company” and “does not warrant further engagement,” and that the plan would give the board time to evaluate other proposals. The board’s statement emphasized that the rights plan protects stockholder interests and ensures fair treatment while providing flexibility to assess transaction proposals.
Rezolve’s criticism centers on the belief that the poison pill is a “white flag” that dilutes shareholders and stifles growth. CEO Daniel M. Wagner said, “One week after Rezolve Ai took its case directly to Commerce.com’s shareholders, their Board’s response was not engagement, not dialogue, not a counter‑proposal – it was the adoption of a poison pill.” He added, “A Board forecasting growth of 1.5% has chosen to try to lock its shareholders out of a proposal that implies more than double the current share price, rather than let them decide for themselves. The Commerce.com Board has poisoned its own well.” Wagner also noted that Rezolve’s Brain Suite would give merchants conversational commerce capability, AI‑native infrastructure, and a proprietary payment rail that Commerce.com’s current platform cannot deliver, and that Rezolve does not need Commerce.com to execute its strategy.
Commerce.com’s financials provide context for the board’s defensive stance. In FY 2025 the company reported total revenue of $342.3 million, a 3% increase versus the prior year, and total ARR of $359.1 million, also up 3% YoY, with enterprise ARR rising 10% YoY. The company’s growth forecast for 2026 is only 1.5%, a sharp contrast to Rezolve’s projected 7.5‑fold year‑on‑year growth and full‑year guidance of $360 million based on contracted 2026 revenue of $232 million. Rezolve’s offer values Commerce.com at more than double its current share price, based on a 47% discount to the April 7 closing price of $2.88. The board’s adoption of the poison pill is therefore seen by Rezolve as an attempt to entrench a failing board and prevent shareholders from realizing value.
The statement also highlights the upcoming shareholder vote on May 14, 2026, when directors will be elected. Rezolve views this election as an opportunity for shareholders to express dissatisfaction with the current board’s leadership. The board’s legal assessment is ongoing, with Rezolve evaluating whether the rights plan complies with applicable law and whether the board’s adoption aligns with fiduciary duties. The event is material because it directly impacts shareholder rights, potential takeover dynamics, and the strategic direction of both companies.
The statement underscores a broader strategic clash: Rezolve’s AI‑native commerce platform contrasts with Commerce.com’s legacy platform, and Rezolve’s aggressive stance reflects its belief that the board’s defensive move is detrimental to shareholder value and the company’s future growth. The poison pill’s dilution effect and the board’s justification for the plan illustrate the tension between defensive governance and shareholder interests in a rapidly evolving AI‑driven commerce landscape.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.